[{"orgOrder":0,"company":"Numab Therapeutics","sponsor":"Kaken Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Licensing Agreement","leadProduct":"NM26-2198","moa":"IL-4R-alpha\/IL-31 receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"Numab Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Numab Therapeutics \/ Kaken Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Numab Therapeutics \/ Kaken Pharmaceuticals"},{"orgOrder":0,"company":"Numab Therapeutics","sponsor":"Cormorant Asset Management","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody","year":"2025","type":"Series C Financing","leadProduct":"NM26-2198","moa":"IL-4R-alpha\/IL-31 receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"Numab Therapeutics","amount2":0.20000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0.20000000000000001,"dosageForm":"Subcutaneous Injection","sponsorNew":"Numab Therapeutics \/ Cormorant Asset Management","highestDevelopmentStatusID":"6","companyTruncated":"Numab Therapeutics \/ Cormorant Asset Management"},{"orgOrder":0,"company":"Numab Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"NM26-2198","moa":"IL-4R-alpha\/IL-31 receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"Numab Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Numab Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Numab Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Numab Therapeutics","sponsor":"Johnson & Johnson","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody","year":"2024","type":"Acquisition","leadProduct":"NM26-2198","moa":"IL-4R-alpha\/IL-31 receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"Numab Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Numab Therapeutics \/ Johnson & Johnson","highestDevelopmentStatusID":"6","companyTruncated":"Numab Therapeutics \/ Johnson & Johnson"},{"orgOrder":0,"company":"Numab Therapeutics","sponsor":"Kaken Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"NM26-2198","moa":"IL-4R-alpha\/IL-31 receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"Numab Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Numab Therapeutics \/ Kaken Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Numab Therapeutics \/ Kaken Pharmaceuticals"},{"orgOrder":0,"company":"Numab Therapeutics","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Numab Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Numab Therapeutics \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"2","companyTruncated":"Numab Therapeutics \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Numab Therapeutics","sponsor":"Kaken Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Other Large Molecule","year":"2024","type":"Collaboration","leadProduct":"ND081","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Numab Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Numab Therapeutics \/ Kaken Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Numab Therapeutics \/ Kaken Pharmaceuticals"},{"orgOrder":0,"company":"Numab Therapeutics","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Undisclosed","year":"2022","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Numab Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Numab Therapeutics \/ Ono Pharmaceutical","highestDevelopmentStatusID":"3","companyTruncated":"Numab Therapeutics \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Numab Therapeutics","sponsor":"3S Bio Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Series B Financing","leadProduct":"ND021","moa":"4-1BB","graph1":"Oncology","graph2":"IND Enabling","graph3":"Numab Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Numab Therapeutics \/ 3S Bio Inc","highestDevelopmentStatusID":"5","companyTruncated":"Numab Therapeutics \/ 3S Bio Inc"},{"orgOrder":0,"company":"Numab Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"NM32-2668","moa":"ROR1\/CD3","graph1":"Oncology","graph2":"Phase I","graph3":"Numab Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Numab Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Numab Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Numab Therapeutics","sponsor":"Organovo Holdings","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Series C Financing","leadProduct":"NM21-1480","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Numab Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Numab Therapeutics \/ Organovo Holdings","highestDevelopmentStatusID":"7","companyTruncated":"Numab Therapeutics \/ Organovo Holdings"},{"orgOrder":0,"company":"Numab Therapeutics","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Large Molecule","year":"2024","type":"Collaboration","leadProduct":"NM49","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Numab Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Numab Therapeutics \/ Ono Pharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"Numab Therapeutics \/ Ono Pharmaceutical"}]

Find Clinical Drug Pipeline Developments & Deals by Numab Therapeutics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharma Live Expo
                          Not Confirmed
                          Pharma Live Expo
                          Not Confirmed

                          Details : The Proceeds will be used to support the advancement of multiple first-in-class and best-in-class programs into clinical development, which includes NM26-2198 is being evaluated for atopic dermatitis.

                          Product Name : NM26-2198

                          Product Type : Antibody

                          Upfront Cash : Undisclosed

                          January 09, 2025

                          Lead Product(s) : NM26-2198

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase I

                          Sponsor : Cormorant Asset Management

                          Deal Size : $197.6 million

                          Deal Type : Series C Financing

                          blank

                          02

                          Pharma Live Expo
                          Not Confirmed
                          Pharma Live Expo
                          Not Confirmed

                          Details : The collaboration aims to develop ND081, a potential first-in-class multi-specific antibody for the treatment of inflammatory bowel disease (IBD).

                          Product Name : ND081

                          Product Type : Other Large Molecule

                          Upfront Cash : $14.6 million

                          November 15, 2024

                          Lead Product(s) : ND081

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Preclinical

                          Sponsor : Kaken Pharmaceuticals

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          03

                          Pharma Live Expo
                          Not Confirmed
                          Pharma Live Expo
                          Not Confirmed

                          Details : NM32 is a next generation tri-specific immuno-oncology drug targeting the ROR1 receptor & CD3. It is being evaluated for the treatment of solid tumors.

                          Product Name : NM32

                          Product Type : Other Large Molecule

                          Upfront Cash : Inapplicable

                          October 30, 2024

                          Lead Product(s) : NM32-2668

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Pharma Live Expo
                          Not Confirmed
                          Pharma Live Expo
                          Not Confirmed

                          Details : The agreement aims to acquire NM26, a Phase 2-ready investigational, first-in-class bispecific antibody targeting two clinically proven pathways in atopic dermatitis (AD).

                          Product Name : NM26-2198

                          Product Type : Antibody

                          Upfront Cash : $1,250.0 million

                          May 28, 2024

                          Lead Product(s) : NM26-2198

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase I

                          Sponsor : Johnson & Johnson

                          Deal Size : $1,250.0 million

                          Deal Type : Acquisition

                          blank

                          05

                          Pharma Live Expo
                          Not Confirmed
                          Pharma Live Expo
                          Not Confirmed

                          Details : Ono obtained rights for NM49 from Numab for global development and commercialization. NM49 is a multi-specific antibody designed to activate tumor-associated macrophage phagocytosis for cancer.

                          Product Name : NM49

                          Product Type : Other Large Molecule

                          Upfront Cash : Undisclosed

                          February 14, 2024

                          Lead Product(s) : NM49

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Ono Pharmaceutical

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          06

                          Pharma Live Expo
                          Not Confirmed
                          Pharma Live Expo
                          Not Confirmed

                          Details : NM26/NM26-2198, a first-in-class bi-specific antibody for the treatment of moderate-to-severe atopic dermatitis (AD). MAD data expected to be reported in mid-2024; Single ascending dose (SAD) cohort in healthy volunteers remains ongoing.

                          Product Name : NM26-2198

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          October 19, 2023

                          Lead Product(s) : NM26-2198

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          Pharma Live Expo
                          Not Confirmed
                          Pharma Live Expo
                          Not Confirmed

                          Details : NM26-2198 is a bi-specific antibody which targets IL-4Rα (type I and type II receptors) and IL-31 for the treatment of moderate-to-severe atopic dermatitis (AD).

                          Product Name : NM26-2198

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          May 15, 2023

                          Lead Product(s) : NM26-2198

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase I

                          Sponsor : Kaken Pharmaceuticals

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          Pharma Live Expo
                          Not Confirmed
                          Pharma Live Expo
                          Not Confirmed

                          Details : Under the terms of the license agreement, Ono acquires intellectual property rights and exclusive global development and commercialization rights for a multispecific antibody targeting a novel immuno-oncology target.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          March 31, 2022

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Discovery Platform

                          Sponsor : Ono Pharmaceutical

                          Deal Size : $276.6 million

                          Deal Type : Licensing Agreement

                          blank

                          09

                          Pharma Live Expo
                          Not Confirmed
                          Pharma Live Expo
                          Not Confirmed

                          Details : Proceeds will support acceleration and expansion of the clinical development of Numab’s lead program NM21-1480 into multiple cancer indications, and the advancement of the company’s pipeline of multi-specific antibodies in oncology and inflammation, ...

                          Product Name : NM21-1480

                          Product Type : Antibody

                          Upfront Cash : Undisclosed

                          May 20, 2021

                          Lead Product(s) : NM21-1480

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Organovo Holdings

                          Deal Size : $110.0 million

                          Deal Type : Series C Financing

                          blank

                          10

                          Pharma Live Expo
                          Not Confirmed
                          Pharma Live Expo
                          Not Confirmed

                          Details : Under the expanded agreement, Kaken receives commercial rights for NM26-2198 in Japan, China, South Korea, Taiwan, Singapore, and Hong Kong, while Numab retains the commercial rights to the US, Europe, and the rest of the world.

                          Product Name : NM26-2198

                          Product Type : Antibody

                          Upfront Cash : Undisclosed

                          January 13, 2021

                          Lead Product(s) : NM26-2198

                          Therapeutic Area : Dermatology

                          Highest Development Status : IND Enabling

                          Sponsor : Kaken Pharmaceuticals

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank